Malignancy Rates in Brodalumab Clinical Studies for Psoriasis

ConclusionsRates of malignancy among brodalumab-treated patients with psoriasis were generally low.Trial registryClinicalTrials.gov identifier NCT00975637; NCT01101100; NCT01708590 (AMAGINE-1); NCT01708603 (AMAGINE-2); NCT01708629 (AMAGINE-3).

http://link.springer.com/10.1007/s40257-020-00512-4

Source: American Journal of Clinical Dermatology - March 22, 2020 Category: Dermatology Source Type: research